A Positive Opioid Screen Does Not Establish Impairment

October 14, 2026 | The Psychiatric Record | Clinical Assessment

Three questions can be hidden inside the phrase "positive opioid test."

What did this assay detect? Has the finding been confirmed? Is the patient clinically impaired now?

A psychiatric assessment can go wrong when a laboratory flag becomes a conclusion about intoxication before anyone has clarified the test's scope or examined the patient.

The clinical response should neither dismiss the finding nor give it authority it does not possess.

The American College of Medical Toxicology's statement on urine opiate and opioid testing emphasizes that there is no universal opioid test. Many clinical opiate immunoassays primarily target morphine and codeine. Oxycodone, buprenorphine, methadone and fentanyl require their own assays for reliable detection; the laboratory can clarify whether these are included in the ordered panel. A negative assay that is not specific for fentanyl cannot exclude fentanyl exposure.

That makes the name of the ordered panel an opening question, not a sufficient description of its contents. The clinical team needs to know which assay produced the result and what substances it was designed to identify.

For an unexpected finding, the laboratory is a useful partner. The question can be concrete: what does this reported result establish with this method, and what further testing would answer the uncertainty that matters to this patient's care?

The same discipline applies to a result that seems to confirm the clinician's suspicion. An expected answer still needs accurate interpretation. Confidence in the history does not expand the assay's capabilities.

ACMT distinguishes preliminary immunoassay screening from more specific chromatographic confirmation and recommends confirmation for high-consequence clinical uses. Cross-reactivity depends on the assay; a generic list of substances that can cause false positives cannot settle an individual result.

The FDA makes a related point in its guidance specifically for home-use drug tests: a preliminary positive should undergo laboratory confirmation, and medicines and other factors can affect the home result. That consumer testing workflow should not be presented as the specification for every hospital test.

Confirmation may help identify a substance more specifically. It does not determine the patient's present clinical condition or guarantee that the initial result will be overturned.

ACMT states that urinary opioid findings do not establish the dose, precise timing or intent of exposure, and that a positive result alone does not establish clinical impairment. Even a confirmed finding cannot substitute for that assessment.

This distinction is easy to lose in a chart. "Screen positive" can become "intoxicated" as one note is copied into the next. The second phrase makes a clinical claim that the first phrase did not establish.

An accurate account can preserve the laboratory result, its confirmation status and the observed clinical findings separately. It can also identify what remains unknown. That is more useful than forcing all available information into a single reassuring or alarming label.

There is an equally important error in the other direction: treating uncertainty about the assay as a reason to postpone care. ACMT states that management of acute opioid poisoning rests on clinical findings and should not be delayed for test results.

The analytical and clinical tasks can proceed on different timelines. A patient who needs urgent assessment and treatment needs that response even while the laboratory question remains open. Conversely, a positive screen without a demonstrated clinical finding should not be rewritten as an examination that never occurred.

Before using the result to justify a consequential decision, identify the question the decision requires. If the question is what the assay detected, clarify the assay. If it is whether confirmation is needed, discuss the appropriate method. If it is how the patient is doing now, assess the patient.

The laboratory can answer an important part of the encounter. It cannot conduct the encounter for us.

Source note: This commentary applies the cited testing guidance; it reports no new study or validated assessment instrument.

Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Appropriate assessment and treatment depend on the individual, setting, and current authoritative guidance. Patients should coordinate treatment decisions with their treating clinicians. This article is not a forensic opinion or an emergency treatment protocol.